Latest filing published 16 Jul 2026 for PTC Therapeutics, INC., €246k.
Across 1 buy signal with a settled T+90 return. Return basis: close on the day after publication.
This profile gathers the share dealings of Pierre Gravier in PTC Therapeutics, Inc. We count 13 filings; the first trade dates from 13 July 2023 and the latest from 14 July 2026.
On the open market, the record shows 1 purchase worth €185k and 7 sales worth €852k. Sales outweigh purchases by €668k. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 5 share grants. Since January 2026: no purchases and 3 sales on the market.
On 16 July 2026 came the latest disclosure, an open-market sale for €246k in PTC Therapeutics, Inc. The clock since the last published purchase (14 December 2023) now reads 1,045 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
11 of 11 declarations